Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer

Journal of Cancer Research & Clinical Oncology, 03/19/2012

The authors confirmed the predictive role of an increase in circulating endothelial cell (CEC) in metastatic colorectal cancer (mCRC) patients treated with Bevacizumab–based therapy and showed that modifications in CECs and circulating endothelial cell (CEC) number, their apoptotic fraction (APO–CEC) are independent factors. This underlines the relevance of a simultaneous quantitative and functional evaluation of these biomarkers in view of their possible diagnostic utility.

Print Article Summary Cat 2 CME Report